These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 34404115)

  • 1. Perspective on model-informed drug development.
    Lesko LJ
    CPT Pharmacometrics Syst Pharmacol; 2021 Oct; 10(10):1127-1129. PubMed ID: 34404115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opportunities and challenges for applying model-informed drug development approaches to gene therapies.
    Belov A; Schultz K; Forshee R; Tegenge MA
    CPT Pharmacometrics Syst Pharmacol; 2021 Apr; 10(4):286-290. PubMed ID: 33608998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Commentary on Fit-For-Purpose Models for Regulatory Applications.
    Wang Y; Huang SM
    J Pharm Sci; 2019 Jan; 108(1):18-20. PubMed ID: 30244011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of PBPK Modeling and Simulation for Regulatory Decision Making and Its Impact on US Prescribing Information: An Update on the 2018-2019 Submissions to the US FDA's Office of Clinical Pharmacology.
    Zhang X; Yang Y; Grimstein M; Fan J; Grillo JA; Huang SM; Zhu H; Wang Y
    J Clin Pharmacol; 2020 Oct; 60 Suppl 1():S160-S178. PubMed ID: 33205429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Industry Perspective on Using MIDD for Pediatric Studies Requiring Integration of Ontogeny.
    Corriol-Rohou S; Cheung SYA
    J Clin Pharmacol; 2019 Sep; 59 Suppl 1():S112-S119. PubMed ID: 31502694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Prescription Drug User Fee Act: Much More Than User Fees.
    Mitchell AP; Trivedi NU; Bach PB
    Med Care; 2022 Apr; 60(4):287-293. PubMed ID: 35149663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biopharmaceutics Applications of Physiologically Based Pharmacokinetic Absorption Modeling and Simulation in Regulatory Submissions to the U.S. Food and Drug Administration for New Drugs.
    Wu F; Shah H; Li M; Duan P; Zhao P; Suarez S; Raines K; Zhao Y; Wang M; Lin HP; Duan J; Yu L; Seo P
    AAPS J; 2021 Feb; 23(2):31. PubMed ID: 33619657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective.
    Shebley M; Sandhu P; Emami Riedmaier A; Jamei M; Narayanan R; Patel A; Peters SA; Reddy VP; Zheng M; de Zwart L; Beneton M; Bouzom F; Chen J; Chen Y; Cleary Y; Collins C; Dickinson GL; Djebli N; Einolf HJ; Gardner I; Huth F; Kazmi F; Khalil F; Lin J; Odinecs A; Patel C; Rong H; Schuck E; Sharma P; Wu SP; Xu Y; Yamazaki S; Yoshida K; Rowland M
    Clin Pharmacol Ther; 2018 Jul; 104(1):88-110. PubMed ID: 29315504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Model-Informed Drug Development in Pediatric Dose Selection.
    Bi Y; Liu J; Li F; Yu J; Bhattaram A; Bewernitz M; Li RJ; Ahn J; Earp J; Ma L; Zhuang L; Yang Y; Zhang X; Zhu H; Wang Y
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S60-S69. PubMed ID: 34185906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transforming Evidence Generation for Drug Label Changes: A Case Study.
    Desborough L; Jaffe K; Hanna J; Ulloa J; Kaiserman K
    Ann Biomed Eng; 2023 Jan; 51(1):137-149. PubMed ID: 36070049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consideration of a Credibility Assessment Framework in Model-Informed Drug Development: Potential Application to Physiologically-Based Pharmacokinetic Modeling and Simulation.
    Kuemmel C; Yang Y; Zhang X; Florian J; Zhu H; Tegenge M; Huang SM; Wang Y; Morrison T; Zineh I
    CPT Pharmacometrics Syst Pharmacol; 2020 Jan; 9(1):21-28. PubMed ID: 31652029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Model-Informed Drug Development for Anti-Infectives: State of the Art and Future.
    Rayner CR; Smith PF; Andes D; Andrews K; Derendorf H; Friberg LE; Hanna D; Lepak A; Mills E; Polasek TM; Roberts JA; Schuck V; Shelton MJ; Wesche D; Rowland-Yeo K
    Clin Pharmacol Ther; 2021 Apr; 109(4):867-891. PubMed ID: 33555032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacometrics and systems pharmacology for metabolic bone diseases.
    Riggs MM; Cremers S
    Br J Clin Pharmacol; 2019 Jun; 85(6):1136-1146. PubMed ID: 30690761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Call for Objective Dose Selection to Increase Success in Pediatric Clinical Trials: A Perspective From NICHD and NIMH Program Staff.
    Giacoia G; Grabb MC; Pawlyk AC; Ren Z; Samedy-Bates L; Taylor-Zapata P
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S9-S12. PubMed ID: 34185908
    [No Abstract]   [Full Text] [Related]  

  • 15. Physiologically Based Pharmacokinetic Modeling in Regulatory Science: An Update From the U.S. Food and Drug Administration's Office of Clinical Pharmacology.
    Grimstein M; Yang Y; Zhang X; Grillo J; Huang SM; Zineh I; Wang Y
    J Pharm Sci; 2019 Jan; 108(1):21-25. PubMed ID: 30385284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crosstalk of physiological pH and chemical pKa under the umbrella of physiologically based pharmacokinetic modeling of drug absorption, distribution, metabolism, excretion, and toxicity.
    Gaohua L; Miao X; Dou L
    Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1103-1124. PubMed ID: 34253134
    [No Abstract]   [Full Text] [Related]  

  • 17. Model-Informed Drug Development: Current US Regulatory Practice and Future Considerations.
    Wang Y; Zhu H; Madabushi R; Liu Q; Huang SM; Zineh I
    Clin Pharmacol Ther; 2019 Apr; 105(4):899-911. PubMed ID: 30653670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review: Role of Model-Informed Drug Development Approaches in the Lifecycle of Drug Development and Regulatory Decision-Making.
    Madabushi R; Seo P; Zhao L; Tegenge M; Zhu H
    Pharm Res; 2022 Aug; 39(8):1669-1680. PubMed ID: 35552984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Applications, Challenges, and Outlook for PBPK Modeling and Simulation: A Regulatory, Industrial and Academic Perspective.
    Lin W; Chen Y; Unadkat JD; Zhang X; Wu D; Heimbach T
    Pharm Res; 2022 Aug; 39(8):1701-1731. PubMed ID: 35552967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review.
    Zhao P; Zhang L; Grillo JA; Liu Q; Bullock JM; Moon YJ; Song P; Brar SS; Madabushi R; Wu TC; Booth BP; Rahman NA; Reynolds KS; Gil Berglund E; Lesko LJ; Huang SM
    Clin Pharmacol Ther; 2011 Feb; 89(2):259-67. PubMed ID: 21191381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.